Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

35.74 -0.46 (-1.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,227,743
Open 36.25
Bid (Size) 35.58 (2)
Ask (Size) 35.95 (1)
Prev. Close 36.20
Today's Range 35.56 - 37.42
52wk Range 34.90 - 173.25
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud
Exposures Legal
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
Exposures Legal

Performance

YTD
-71.2%
-71.2%
1 Month
-34.6%
-34.6%
3 Month
-67.5%
-67.5%
6 Month
-68.2%
-68.2%
1 Year
-73.1%
-73.1%

More News

Read More
Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%
Via Benzinga
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying
Via The Motley Fool
Topics Cannabis Law Enforcement
Exposures Cannabis Legal
Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via NewMediaWire
Topics Fraud
Exposures Legal
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
Exposures Legal
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
Via Benzinga
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via NewMediaWire
Topics Fraud
Exposures Legal
SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
Exposures Legal
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via NewMediaWire
Topics Fraud
Exposures Legal
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
Exposures Legal
Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why
Via StockStory
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up
Via Benzinga
The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low
Via Investor's Business Daily
Topics Death
Exposures Death Product Safety
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
Via Benzinga
Exposures Product Safety
Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results
Via Benzinga
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Porch Group Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Sarepta Shares Slide To 2017 Lows On Revenue Cut, But Retail Bulls Remain Defiant
Via Stocktwits

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
The current price of Sarepta Therapeutics, Inc. - Common Stock is 35.74
When was Sarepta Therapeutics, Inc. - Common Stock last traded?
The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 05/14/25 04:00 PM ET
What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 3.33B
How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
Sarepta Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.